Treatment Advances

Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Azer-cel, a New CAR T-Cell Therapy for DLBCL

November 08, 2024

Explore an innovative trial using Azer-cel, an allogeneic CAR T-cell therapy, for relapsed DLBCL patients, focusing on safety and effectiveness.

How One DLBCL Therapy Is Proving Its Worth: Three Years Later

October 15, 2024

After three years since its original Phase III trial, lisocabtagene maraleucel (liso-cel) is still proving effective for relapsed/refractory DLBCL patients.

Large B-Cell Lymphoma with CNS Involvement: Treatment Options and Future Directions

September 16, 2024

Learn about the challenges of treating DLBCL with central nervous system involvement, explore available treatment options, and discover the latest research.

Making CAR-T Therapy Safer and More Accessible for DLBCL Patients

August 29, 2024

CAR-T therapy side effects in DLBCL patients are rare after two weeks, but how long should patients be monitored?

Is Age Just A Number? Analyzing CAR T-cell Therapy for B-cell Lymphoma

July 22, 2024

Is age just a number? Dr. Julio Chavez shares multicenter findings on how CAR T therapy can be effective in those 80 and older.

New Bispecific Antibody AZD0486 for Relapsed/Refractory Lymphoma

July 17, 2024

Discover insights from Dr. Ryan Jacobs on AZD0486, a new bispecific antibody for relapsed or refractory lymphoma patients.

CAR T-Cell Therapy Advances in Large B Cell Lymphoma

June 18, 2024

Dr. David Miklos joins HealthTree Foundation to discuss CAR T-cell advances and what they mean for DLBCL patients.

Relapsed DLBCL Treatment Options: Exploring Loncastuximab Tesirine (Zynlonta)

May 31, 2024

Learn about Loncastuximab Tesirine (Zynlonta), an FDA-approved conjugated antibody for patients with relapsed or refractory DLBCL.

Factors that Influence Blood Transfusion Needs for DLBCL Patients Receiving CAR T-Cell Therapy

May 09, 2024

Researchers studied whether certain factors influence the need for blood transfusions in DLBCL patients receiving CAR T-cell therapy.

Bispecific Antibodies for Relapsed/Refractory DLBCL

May 02, 2024

Explore Bispecific Antibodies, a promising new treatment option for relapsed/refractory DLBCL. Learn how they work, side effects, and approved therapies.